The Economist explores the market for expensive cancer treatments:
The government health programme for the elderly is barred from considering price at all when it decides whether to cover injected drugs under something called Medicare Part B. Under Part B’s loopy reimbursement system, the more a drug costs, the more the oncologist who prescribes it is paid. Patients have little reason to demand cheaper drugs.
The Dish 